EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

European Journal of Cancer

Volumn 48, Issue 5, 2012, Pages 599-641

  Llovet, Josep M ^a   Ducreux, Michel ^b   Lencioni, Riccardo ^c   Di Bisceglie, Adrian M ^c   Galle, Peter R ^c   Dufour, Jean Francois ^c   Greten, Tim F ^c   Raymond, Eric ^c   Roskams, Tania ^c   De Baere, Thierry ^c   Mazzaferro, Vincenzo ^c   Bernardi, M ^a   Bruix, Jordi ^c   Colombo, Massimo ^c   Zhu, Andrew ^c  

^a EASL Office   (Switzerland)

^b EORTC   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AXITINIB; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; LAPATINIB; LINIFANIB; NOLATREXED; OXALIPLATIN; PLACEBO; RAMUCIRUMAB; RAPAMYCIN; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; UNINDEXED DRUG; VANDETANIB; VATALANIB; YTTRIUM 90;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CATHETERIZATION; CHEMOEMBOLIZATION; CHRONIC HEPATITIS; COLORECTAL CANCER; DIARRHEA; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LIVING DONOR; LUNG NON SMALL CELL CANCER; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SKIN MANIFESTATION;

EID: 84995268963     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.021     Document Type: Article

References (360)

1. J. Bruix, M. Sherman, and J.M. Llovet EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430 (Pubitemid 32844200)
2. National Cancer Institute. PDQ® Levels of Evidence for Adult and Pediatric Cancer Treatment Studies. Bethesda, MD: National Cancer Institute. Date last modified 26/August/2010. Available from: http://cancer.gov/ cancertopics/pdq/levels-evidence-adult-treatment/healthprofessional/ [accessed March 1st, 2011].
3. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
4. IARC. Available from: http://www-dep.iarc.fr: [accessed November 1st, 2011].
5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750. (Pubitemid 29114292)
6. H. Tanaka, Y. Imai, and N. Hiramatsu Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003 Ann Intern Med 148 2008 820 826 (Pubitemid 351786929)
7. C. Bosetti, P. Boffetta, F. Lucchini, E. Negri, and C. La Vecchia Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004 Hepatology 48 2008 137 145 (Pubitemid 351980469)
8. A. Jemal, R. Siegel, and E. Ward Cancer Statistics, 2008 CA Cancer J Clin 58 2008 71 96 (Pubitemid 351521864)
9. M.H. Chang, S.L. You, and C.J. Chen Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study J Natl Cancer Inst 101 2009 1348 1355
10. A. Sangiovanni, G.M. Prati, and P. Fasani The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients Hepatology 43 2006 1303 1310 (Pubitemid 43980109)
11. G. Ioannou, M. Splan, and N. Weiss Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis Clin Gastroenterol Hepatol 5 2007 938 945
12. A.S. Lok, L.B. Seeff, and T.R. Morgan Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease Gastroenterology 136 2009 138 148
13. C. Ripoll, R.J. Groszmann, and G. Garcia-Tsao Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis J Hepatol 50 2009 923 928
14. R. Masuzaki, R. Tateishi, and H. Yoshida Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography Hepatology 49 2009 1954 1961
15. K.S. Jung, S.U. Kim, and S.H. Ahn Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) Hepatology 53 2011 885 894
16. A.S. Lok Prevention of hepatitis B virus-related hepatocellular carcinoma Gastroenterology 127 2004 S303 309
17. H.I. Yang, S.N. Lu, and Y.F. Liaw Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 2002 168 174
18. C.J. Chen, H.I. Yang, and J. Su REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73 (Pubitemid 43042691)
19. M.W. Yu, S.H. Yeh, and P.J. Chen Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men J Natl Cancer Inst 97 2005 265 272
20. U.H. Iloeje, H.I. Yang, and J. Su Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 2006 678 686
21. S. Raimondi, S. Bruno, M.U. Mondelli, and P. Maisonneuve Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis J Hepatol 50 2009 1142 1154
22. I.C. Hsu, R.A. Metcalf, and T. Sun Mutational hotspot in the p53 gene in human hepatocellular carcinomas Nature 350 1991 427 428 (Pubitemid 21912245)
23. Y.M. Deugnier, D. Guyader, and L. Crantock Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases Gastroenterology 104 1993 228 234 (Pubitemid 23040027)
24. D.H. Perlmutter Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency Pediatr Res 60 2006 233 238 (Pubitemid 44297600)
25. J. Polio, R.E. Enriquez, A. Chow, W.M. Wood, and C.E. Atterbury Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature J Clin Gastroenterol 11 1989 220 224 (Pubitemid 19104448)
26. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001;96:2462-67. (Pubitemid 32769212)
27. J. Marrero, R. Fontana, and S. Fu Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma J Hepatol 42 2005 218 224 (Pubitemid 40143468)
28. D. Trichopoulos, C. Bamia, and P. Lagiou Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study J Natl Cancer Inst. 103 2011 1686 1695
29. P. Marcellin, F. Pequignot, and E. Delarocque-Astagneau Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption J Hepatol 48 2008 200 207
30. Y. Miki, J. Swensen, and D. Shattuck-Eidens A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 Science 266 1994 66 71 (Pubitemid 24345325)
31. G. Marra, and C.R. Boland Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives J Natl Cancer Inst 87 1995 1114 1125
32. K.K. Tanabe, A. Lemoine, and D.M. Finkelstein Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis JAMA 299 2008 53 60
33. R.J. Clifford, J. Zhang, and D.M. Meerzaman Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma Hepatology 52 2010 2034 2043
34. Hepatitis B vaccines. Weekly epidemiological record of the World Health Organization 2009;84,405-20.
35. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B J Hepatol 50 2009 227 242
36. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of hepatitis C virus infection J Hepatol 55 2011 245 264
37. C. Niederau, T. Heintges, and S. Lange Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B N Engl J Med 334 1996 1422 1427 (Pubitemid 26157437)
38. M.F. Yuen, E. Sablon, and C.K. Hui Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 2001 785 791 (Pubitemid 32928004)
39. Y.F. Liaw, J.J. Sung, and W.C. Chow Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
40. A.G. Singal, M.L. Volk, D. Jensen, A.M. Di Bisceglie, and P.S. Schoenfeld A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus Clin Gastroenterol Hepatol 8 2010 280 288
41. S. Nishiguchi, T. Kuroki, and S. Nakatani Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
42. D.C. Valla, M. Chevallier, and P. Marcellin Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment Hepatology 29 1999 1870 1875 (Pubitemid 29247063)
43. A.S. Lok, J.E. Everhart, and E.C. Wright HALT-C Trial Group. Maintenance Peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C Gastroenterology 140 2011 840 849
44. A.M. Di Bisceglie, A.M. Stoddard, and J.L. Dienstag HALT-C Trial Group. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon Hepatology 53 2011 1100 1108
45. J. Bruix, T. Poynard, and M. Colombo EPIC3 Study Group. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C Gastroenterology 140 2011 1990 1999
46. P.C. Prorok Epidemiologic approach for cancer screening. Problems in design and analysis of trials Am J Pediatr Hematol Oncol 14 1992 117 128
47. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
48. A. Laupacis, D. Feeny, A.S. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 1992 473 481
49. F.P. Sarasin, E. Giostra, and A. Hadengue Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis Am J Med 101 1996 422 434 (Pubitemid 26392861)
50. G. Fattovich, T. Stroffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 2004 S35 50
51. H. Yoshida, Y. Shiratori, and M. Moriyama Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy Ann Intern Med 131 1999 174 181 (Pubitemid 29364999)
52. A. Sangiovanni, E. Del Ninno, and P. Fasani Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance Gastroenterology 126 2004 1005 1014 (Pubitemid 38451172)
53. Ganne-Carrié N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996;23:1112-18.
54. R.F. Velázquez, M. Rodríguez, and C.A. Navascués Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis Hepatology 37 2003 520 527 (Pubitemid 36258772)
55. F. Trevisani, V. Santi, and A. Gramenzi For the Italian Liver Cancer (ITA.LI.CA.) group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol 102 2007 2448 2457 (Pubitemid 47631760)
56. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
57. A.M. Di Bisceglie Issues in screening and surveillance for hepatocellular carcinoma Gastroenterology 127 2004 S104 107
58. G. Fattovich, F. Bortolotti, and F. Donato Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors J Hepatol 48 2008 335 352
59. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-56. (Pubitemid 35408309)
60. S.M. Martínez, G. Crespo, M. Navasa, and X. Forns Noninvasive assessment of liver fibrosis Hepatology 53 2011 325 335
61. F.X. Bosch, J. Ribes, M. Díaz, and R. Cléries Primary liver cancer: worldwide incidence and trends Gastroenterology 127 2004 Nov S5 S16
62. K. Yasui, E. Hashimoto, and Y. Komorizono Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma Clin Gastroenterol Hepatol 9 2011 428 433
63. A. Crax, and C. Cammà Prevention of hepatocellular carcinoma Clin Liver Dis 9 2005 329 346
64. S. Bruno, T. Stroffolini, and M. Colombo Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587 (Pubitemid 46453759)
65. J.J. Sung, K.K. Tsoi, V.W. Wong, K.C. Li, and H.L. Chan Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 2008 1067 1077
66. P. Lampertico, M. Vigan, and E. Manenti Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 2007 1445 1451 (Pubitemid 350047463)
67. L. Bolondi Screening for hepatocellular carcinoma in cirrhosis J Hepatol 39 2003 1076 1084 (Pubitemid 37523784)
68. C.K. Kim, J.H. Lim, and W.J. Lee Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients J Ultrasound Med 20 2001 99 104
69. A. Singal, M.L. Volk, and A. Waljee Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis Aliment Pharmacol Ther 30 2009 37 47
70. T. Sato, R. Tateishi, and H. Yoshida Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C Hepatol Int 3 2009 544 550
71. R. Lencioni, F. Piscaglia, and L. Bolondi Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma J Hepatol 48 2008 848 857
72. J.A. Marrero, G.L. Su, and W. Wei Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients Hepatology 37 2003 1114 1121 (Pubitemid 36538688)
73. H. Tsukuma, T. Hiyama, and S. Tanaka Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1993 1797 1801 (Pubitemid 23174709)
74. J.G. Chen, D.M. Parkin, and Q.G. Chen Screening for liver cancer: results of a randomised controlled trial in Qidong, China J Med Screen 10 2003 204 209 (Pubitemid 38091209)
75. B.J. McMahon, L. Bulkow, and A. Harpster Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study Hepatology 32 2000 842 846
76. A.M. Di Bisceglie, R.K. Sterling, and R.T. Chung HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C trial J Hepatol 43 2005 434 441 (Pubitemid 41111424)
77. T. Yamashita, M. Forgues, and W. Wang EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma Cancer Res 68 2008 1451 1461 (Pubitemid 351346853)
78. A. Villanueva, B. Minguez, A. Forner, M. Reig, and J.M. Llovet Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy Annu Rev Med 61 2010 317 328
79. Y. Hoshida, S.M. Nijman, and M. Kobayashi Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Cancer Res 69 2009 7385 7392
80. F. Trevisani, P.E. D'Intino, and A.M. Morselli-Labate Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbsAg and anti-HCV status J Hepatol 34 2001 570 575 (Pubitemid 32328514)
81. D. Pateron, N. Ganne, and J.C. Trinchet Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis J Hepatol 20 1994 65 71 (Pubitemid 24043087)
82. Y. Koike, Y. Shiratori, and S. Sato Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients Cancer 91 2001 561 569 (Pubitemid 32105702)
83. R.K. Sterling, L. Jeffers, and F. Gordon Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis Am J Gastroenterol 102 2007 2196 2205 (Pubitemid 47493844)
84. M. Wang, R.E. Long, and M.A. Comunale Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma Cancer Epidemiol Biomarkers Prev 18 2009 1914 1921
85. B. Zhang, and B. Yang Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer J Med Screen 6 1999 108 110 (Pubitemid 29320849)
86. B.H. Zhang, B.H. Yang, and Z.Y. Tang Randomized controlled trial of screening for hepatocellular carcinoma J Cancer Res Clin Oncol 130 2004 417 422
87. L. Barbara, G. Benzi, and S. Gaiani Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival Hepatology 16 1992 132 137
88. M. Ebara, M. Ohto, and T. Shinagawa Natural history of minute hepatocellular carcinoma smaller than three centimetres complicating cirrhosis. A study in 22 patients Gastroenterology 90 1986 289 298 (Pubitemid 16136667)
89. J.C. Sheu, J.L. Sung, and D.S. Chen Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications Gastroenterology 89 1985 259 266
90. M. Makuuchi, N. Kokudo, and S. Arii Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan Hepatol Res 38 2008 37 51 (Pubitemid 350182575)
91. J.C. Trinchet, C. Chaffaut, V. Bourcier for the Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH) Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities Hepatology 54 2011 1987 1997
92. E. Santagostino, M. Colombo, and M. Rivi A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus Blood 102 2003 78 82 (Pubitemid 36759638)
93. J. Thompson Coon, G. Rogers, P. Hewson, D. Wright, and R. Anderson Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis Health Technol Assess 11 2007 1 206
94. F. Trevisani, M.C. Cantarini, and A.M. Morselli Labate Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis. Effects on cancer staging and patients survival Am J Gastroenterol 99 2004 1470 1476 (Pubitemid 39180093)
95. K. Nouso, H. Tanaka, and S. Uematsu Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances J Gastroenterol Hepatol 23 2008 437 444 (Pubitemid 351342062)
96. F. Trevisani, S. De Notariis, and G. Rapaccini Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patients survival (Italian experience) Am J Gastroenterol 97 2002 734 744 (Pubitemid 34245906)
97. V. Santi, F. Trevisani, and A. Gramenzi Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival J Hepatol 53 2010 291 297
98. K.L. Andersson, J.A. Salomon, S.J. Goldie, and R.T. Chung Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis Clin Gastroenterol Hepatol 6 2008 1418 1424
99. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917 (Pubitemid 37518510)
100. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
101. T. Roskams Anatomic Pathology Impact on prognosis and response to therapy Clin Liver Dis 15 2011 245 259
102. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 2008 S20 S37
103. L. Bolondi, S. Gaiani, and N. Celli Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma Hepatology 42 2005 27 34 (Pubitemid 40911308)
104. A. Forner, R. Vilana, and C. Ayuso Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104 (Pubitemid 351171046)
105. T. Roskams, and M. Kojiro Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis Semin Liver Dis 30 2010 17 25
106. S. Terasaki, S. Kaneko, K. Kobayashi, A. Nonomura, and Y. Nakanuma Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study Gastroenterology 115 1998 1216 1222 (Pubitemid 28485613)
107. M. Borzio, S. Fargion, and F. Borzio Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development J Hepatol 39 2003 208 214 (Pubitemid 36920556)
108. R. Stigliano, L. Marelli, and D. Yu Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC Cancer Treat Rev 33 2007 437 447 (Pubitemid 47324228)
109. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
110. A. Sangiovanni, M.A. Manini, and M. Iavarone The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis Gut 59 2010 638 644
111. N.C. Yu, V. Chaudhari, and S.S. Raman CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis Clin Gastroenterol Hepatol. 9 2011 161 167
112. Sersté T, Barrau V, Ozenne V, et al. Accuracy and disagreement of CT and MRI for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. Hepatology 2011. doi:10.1002/hep.24746.
113. J. Rimola, A. Forner, and M. Reig Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma Hepatology 50 2009 791 798
114. R. Lencioni, D. Cioni, C. Della Pina, L. Crocetti, and C. Bartolozzi Imaging diagnosis Semin Liver Dis 25 2005 162 170 (Pubitemid 40781069)
115. International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia Hepatology 49 2009 658 664
116. M.A. Silva, B. Hegab, and C. Hyde Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis Gut 57 2008 1592 1596
117. M. Colombat, V. Paradis, and I. Biche Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis J Pathol 201 2003 260 267 (Pubitemid 37258937)
118. J.M. Llovet, Y. Chen, and E. Wurmbach A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis Gastroenterology 131 2006 1758 1767 (Pubitemid 46001394)
119. E. Wurmbach, Y.B. Chen, and G. Khitrov Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma Hepatology 45 2007 938 947 (Pubitemid 46646500)
120. L. Di Tommaso, G. Franchi, and Y.N. Park Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis Hepatology 45 2007 725 734 (Pubitemid 46450624)
121. M. Capurro, I.R. Wanless, and M. Sherman Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 2003 89 97 (Pubitemid 36799110)
122. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009;50:746-54.
123. Tremosini S, Forner A, Boix L, et al. Biopsy diagnosis of hepatocellular carcinoma <2 cm: prospective validation of glypican 3, heat-shock protein 70 and glutamine synthetase staining in fine needle biopsy samples. ILCA Book of Abstracts, 2011.
124. A. Durnez, C. Verslype, and F. Nevens The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin Histopathology 49 2006 138 151 (Pubitemid 44079697)
125. H. Kim, G.H. Choi, and D.C. Na Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis Hepatology 54 2011 1707 1717
126. A. Colli, M. Fraquelli, and G. Casazza Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review Am J Gastroenterol 101 2006 513 523 (Pubitemid 43340927)
127. M. Burrel, J.M. Llovet, and C. Ayuso MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation Hepatology 38 2003 1034 1042 (Pubitemid 37221687)
128. G. D'Amico, G. Garcia-Tsao, and L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231 (Pubitemid 41772537)
129. K. Okuda, T. Ohtsuki, and H. Obata Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients Cancer 56 1985 918 928 (Pubitemid 15228292)
130. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-55.
131. J.M. Llovet, J. Bustamante, and A. Castells Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 1999 62 67 (Pubitemid 29023987)
132. E. Villa, A. Moles, and I. Ferretti Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival Hepatology 32 2000 233 238 (Pubitemid 30614655)
133. G. Cabibbo, M. Enea, and M. Attanasio A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 2010 1274 1283
134. R.M. Simon, S. Paik, and D.F. Hayes Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 101 2009 1446 1452
135. J. Ji, J. Shi, and A. Budhu MicroRNA expression, survival, and response to interferon in liver cancer N Engl J Med 361 2009 1437 1447
136. A. Villanueva, Y. Hoshida, and C. Battiston Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma Gastroenterology 140 2011 1501 1512
137. Y. Hoshida, A. Villanueva, and M. Kobayashi Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 2008 1995 2004
138. J.M. Llovet, C. Peña, M. Shan, C. Lathia, and J. Bruix Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Presidential Plennary Session, AASLD 59th Annual Meeting, San Francisco Hepatology 48 2008 372A
139. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442 (Pubitemid 36152543)
140. E. Vibert, D. Azuolay, and E. Hoti Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor Am J Transplant 10 2010 127 137
141. C. Toso, J. Trotter, and A. Wei Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma Liver Transpl 8 2008 1107 1115
142. G. N'Kontchou, A. Mahamoudi, and M. Aout Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis Hepatology 50 2009 1475 1483
143. A. Riaz, L. Kulik, and R.J. Lewandowski Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres Hepatology 49 2009 1185 1193
144. S.R. Vora, H. Zheng, Z.K. Stadler, C.S. Fuchs, and A.X. Zhu Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma Oncologist 14 2009 717 725
145. Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Handbook, 7th ed. Liver. New York: Springer; 2010.
146. J.M. Llovet, J. Bruix, and J. Fuster Liver transplantation for treatment of small hepatocellular carcinoma: the TNM classification does not have prognostic power Hepatology 27 1998 1572 1577 (Pubitemid 28264681)
147. S. Chevret, J.C. Trinchet, and D. Mathieu A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome HépatocellulaireGroupe d'Etude et de Traitement du Carcinome Hépatocellulaire J Hepatol 31 1999 133 141
148. J.M. Llovet, C. Brú, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
149. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
150. T.W. Leung, A.M. Tang, and B. Zee Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients Cancer 94 2002 1760 1769 (Pubitemid 34241115)
151. S. Kitai, M. Kudo, and Y. Minami Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score Oncology 75 2008 S83 S90
152. J. Marrero, R.J. Fontana, and A. Barrat Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort Hepatology 41 2005 707 716 (Pubitemid 40462931)
153. U. Cillo, A. Vitale, and F. Grigoletto Prospective validation of the Barcelona Clinic Liver Cancer staging system J Hepatol 44 2006 723 731
154. A. Guglielmi, A. Ruzzenente, and S. Pachera Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response Am J Gastroenterol 103 2008 597 604 (Pubitemid 351405970)
155. M. Kudo Review of 4th Single Topic Conference on HCC. Hepatocellular carcinoma: international consensus and controversies Hepatol Res 37 2007 S83 87
156. T. Takayama, M. Makuuchi, and S. Hirohashi Early hepatocellular carcinoma
157. S. Roayaie, I.N. Blume, and S.N. Thung A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma Gastroenterology 137 2009 850 855
158. Roayaie S, Llovet JM, Obeidat K, et al. Hepatic resection for hepatocellular carcinoma <2 cm in diameter. Hepatology 2012, in press.
159. T. Livraghi, F. Meloni, and M. Di Stasi Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47 2008 82 89 (Pubitemid 351171044)
160. S. Arii, Y. Yamaoka, and S. Futagawa Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan Hepatology 32 2000 1224 1229
161. J.M. Llovet, J. Fuster, and J. Bruix Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation Hepatology 30 1999 1434 1440
162. M. Sala, J.M. Llovet, and R. Vilana Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma Hepatology 40 2004 1352 1360 (Pubitemid 39657009)
163. P.M. Lopez, A. Villanueva, and J.M. Llovet Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials Aliment Pharmacol Ther 23 2006 1535 1547 (Pubitemid 43727460)
164. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
165. K. Takayasu, S. Arii, and I. Ikai Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients Gastroenterology 131 2006 461 469 (Pubitemid 44142456)
166. M. Varela, M.I. Real, and M. Burrel Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 2007 474 481 (Pubitemid 46201723)
167. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization (TACE) using DCBeads. Implications for clinical practice and trial design. J Hepatol 2011, in press
168. J.M. Llovet, S. Ricci, and V. Mazzaferro SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
169. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212-20.
170. Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 2010;28:2889-95.
171. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
172. M.S. Tsao, A. Sakurada, and J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144 (Pubitemid 41058345)
173. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
174. S. Boyault, D.S. Rickman, and A. de Reynis Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets Hepatology 45 2007 42 52 (Pubitemid 46144363)
175. D.Y. Chiang, A. Villanueva, and Y. Hoshida Focal gains of VEGFA and molecular classification of hepatocellular carcinoma Cancer Res 68 2008 6779 6788
176. J.M. Llovet, M. Schwartz, and V. Mazzaferro Resection and liver transplantation for hepatocellular carcinoma Semin Liver Dis 25 2005 181 200 (Pubitemid 40781071)
177. V. Mazzaferro, S. Bhoori, and C. Sposito Milan Criteria in Liver Transplantation for HCC: an Evidence-Based Analysis on 15 Years of Experience Liv Transplant 17 2011 S44 S57
178. J. Belghiti, K. Hiramatsu, and S. Benoist Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection J Am Coll Surg 191 2000 38 46 (Pubitemid 30439557)
179. H. Lang, G.C. Sotiropoulos, and M. Dömland Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis Br J Surg 92 2005 198 202 (Pubitemid 40269334)
180. R.T. Poon, S.T. Fan, and C.M. Lo Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified? Ann Surg 236 2002 602 611 (Pubitemid 35246892)
181. V. Mazzaferro, R. Romito, and M. Schiavo Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis Hepatology 44 2006 1543 1554 (Pubitemid 44970357)
182. T. Ishizawa, K. Hasegawa, and T. Aoki Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma Gastroenterology 134 2008 1908 1916 (Pubitemid 351783260)
183. M. Makuuchi, and K. Sano The surgical approach to HCC: our progress and results in Japan Liver Transpl 10 2004 S46 S52
184. S. Arii, S. Tanaka, and Y. Mitsunori Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography Oncology 78 2010 125 130
185. M. Shi, R.P. Guo, and X.J. Lin Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial Ann Surg. 245 2007 36 43 (Pubitemid 46035433)
186. M. Makuuchi, T. Kosuge, and T. Takayama Surgery for small liver cancers Semin Surg Oncol 9 1993 298 304 (Pubitemid 23216368)
187. J. Bruix, A. Castells, and J. Bosch Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure Gastroenterology 111 1996 1018 1022 (Pubitemid 26327605)
188. K.J. Simpson, and N.D. Finlayson Clinical evaluation of liver disease Baillieres Clin Gastroenterol 9 1995 639 659 (Pubitemid 26012827)
189. A. Cucchetti, F. Piscaglia, and E. Caturelli Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population Ann Surg Oncol 16 2009 413 422
190. O. Farges, J. Belghiti, and R. Kianmanesh Portal vein embolization before right hepatectomy: prospective clinical trial Ann Surg 237 2003 208 217 (Pubitemid 38173248)
191. A. Abulkhir, P. Limongelli, and A.J. Healey Preoperative portal vein embolization for major liver resection: a meta-analysis Ann Surg 247 2008 49 57
192. K.P. Croome, and M.H. Yamashita Laparoscopic vs open hepatic resection for benign and malignant tumors: an updated meta-analysis Arch Surg 145 2010 1109 1118
193. G. Torzilli, N. Olivari, and E. Moroni Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis Liver Transpl 10 2004 S34 S38
194. I. Ikai, S. Arii, and M. Kojiro Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey Cancer 101 2004 796 802 (Pubitemid 39030937)
195. J.N. Vauthey, G.Y. Lauwers, and N.F. Esnaola Simplified staging for hepatocellular carcinoma J Clin Oncol 20 2002 1527 1536 (Pubitemid 34260532)
196. J. Belghiti, Y. Panis, O. Farges, J.P. Benhamou, and F. Fekete Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis Ann Surg 214 1991 114 117
197. S.D. Finkelstein, W. Marsh, and A.J. Demetris Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma Hepatology 37 2003 871 879 (Pubitemid 36397398)
198. H. Imamura, Y. Matsuyama, and E. Tanaka Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J Hepatol 38 2003 200 207 (Pubitemid 36169630)
199. Y. Miyake, A. Takaki, Y. Iwasaki, and K. Yamamoto Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma J Viral Hepat 17 2010 287 292
200. Y.C. Shen, C. Hsu, and L.T. Chen Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach J Hepatol 52 2010 889 894
201. A.G. Singal, A.K. Waljee, M. Shiffman, B.R. Bacon, and P.S. Schoenfeld Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy Aliment Pharmacol Ther 32 2010 969 983
202. S. Yamasaki, H. Hasegawa, and H. Kinoshita A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma Jpn J Cancer Res 87 1996 206 211 (Pubitemid 26099497)
203. W.Y. Lau, T.W. Leung, and S.K. Ho Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial Lancet 353 1999 797 801 (Pubitemid 29110405)
204. E. Boucher, S. Corbinais, and Y. Rolland Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma Hepatology 38 2003 1237 1241 (Pubitemid 37314832)
205. T. Takayama, T. Sekine, and M. Makuuchi Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial Lancet 356 2000 802 807
206. Y. Muto, H. Moriwaki, and M. Ninomiya Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group N Engl J Med 334 1996 1561 1567 (Pubitemid 26177483)
207. Okita K, Matsui O, Kumada H, et al. Peretinoin Study Group. Peretinoin reduces recurrence of hepatocellular carcinoma: Results of a phase II/III randomized placebo-controlled trial. ILCA Book of Abstracts 2010:11A.
208. Yoshida H, Shiratori Y, Kudo M, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011;54:532-40.
209. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009;21:CD001199.
210. S. Iwatsuki, T.E. Starzl, and D.G. Sheahan Hepatic resection versus transplantation for hepatocellular carcinoma Ann Surg 214 1991 221 228
211. S. Iwatsuki, C.O. Esquivel, and R.D. Gordon Liver transplantation for fulminant hepatic failure Semin Liver Dis 5 1985 325 328
212. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699 (Pubitemid 26079803)
213. H. Bismuth, P.E. Majno, and R. Adam Liver transplantation for hepatocellular carcinoma Semin Liver Dis 19 1999 311 322
214. H. Bismuth, L. Chiche, and R. Adam Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis Ann Surg 218 1993 145 151 (Pubitemid 23229140)
215. S. Jonas, W.O. Bechstein, and T. Steinmüller Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis Hepatology 33 2001 1080 1086 (Pubitemid 32378206)
216. ELTR - European Liver Transplant Registry. Available from: www.eltr.org (accessed March 2011).
217. OPTN - Organ Procurement and Transplantation Network. Available from: http://www.ustransplant.org/annual-reports/current/ (accessed March 2011).
218. R.B. Freeman Jr. , R.H. Wiesner, and A. Harper UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy Liver Transpl 8 2002 851 858
219. P.A. Clavien, M. Lesurtel, and P.M. Bossuyt Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report Lancet Oncol 13 2012 e11 e22
220. F.Y. Yao, L. Ferrell, and N.M. Bass Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival Hepatology 33 2001 1394 1403 (Pubitemid 32496976)
221. P.S. Kamath, R.H. Wiesner, and M. Malinchoc A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470 (Pubitemid 32119037)
222. E.A. Pomfret, K. Washburn, and C. Wald Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States Liver Transpl 16 2010 262 278
223. M. Sala, J. Fuster, and J.M. Llovet High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation Liver Transpl 10 2004 1294 1300 (Pubitemid 39406086)
224. V. Mazzaferro, C. Battiston, and S. Perrone Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study Ann Surg 240 2004 900 909 (Pubitemid 39425785)
225. D.S. Lu, N.C. Yu, and S.S. Raman Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation Hepatology 41 2005 1130 1137 (Pubitemid 40593921)
226. P.E. Majno, R. Adam, and H. Bismuth Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis Ann Surg 226 1997 688 701
227. T. Decaens, F. Roudot-Thoraval, and S. Bresson-Hadni Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma Liver Transpl 11 2005 767 775 (Pubitemid 40975578)
228. P.M. Porrett, H. Peterman, and M. Rosen Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era Liver Transpl 12 2006 665 673
229. J.M. Llovet, X. Mas, and J.J. Aponte Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation Gut 50 2002 123 128 (Pubitemid 34028315)
230. A. Vitale, M.L. Volk, and D. Pastorelli Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety Hepatology 51 2010 165 173
231. A.E. Truesdale, S.H. Caldwell, and N.L. Shah Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant Transpl Int 24 2011 991 998
232. F.Y. Yao, L. Xiao, and N.M. Bass Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging Am J Transplant 7 2007 2587 2596 (Pubitemid 47561609)
233. V. Mazzaferro, J.M. Llovet, and R. Miceli Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis Lancet Oncol 10 2009 35 43
234. A. Raj, J. McCall, and E. Gane Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma J Hepatol 55 2011 1063 1068
235. G. Germani, K. Gurusamy, and M. Garcovich Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 17 2011 S58 S66
236. M. Schwartz, I. Dvorchik, and S. Roayaie Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers J Hepatol 49 2008 581 588
237. F.Y. Yao, R.K. Kerlan Jr. , and R. Hirose Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis Hepatology 48 2008 819 827
238. M. Ravaioli, G.L. Grazi, and F. Piscaglia Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria Am J Transplant 8 2008 2547 2557
239. J. Neuberger Liver allocation for patients with hepatocellular carcinoma Liver Transpl 16 2010 249 251
240. S. Bhoori, C. Sposito, A. Germini, J. Coppa, and V. Mazzaferro The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis Transpl Int 23 2010 712 722
241. J.F. Trotter, M. Wachs, G.T. Everson, and I. Kam Adult-to-adult transplantation of the right hepatic lobe from a living donor N Engl J Med 346 2002 1074 1082 (Pubitemid 34984623)
242. P.A. Clavien, H. Petrowsky, M.L. DeOliveira, and R. Graf Strategies for safer liver surgery and partial liver transplantation N Engl J Med 356 2007 1545 1559 (Pubitemid 46588419)
243. J. Bruix, and J.M. Llovet Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology 35 2002 519 524 (Pubitemid 34183954)
244. M. Siegler, M.C. Simmerling, J.H. Siegler, and D.C. Cronin 2nd Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT) Liver Transpl 12 2006 358 360
245. R.M. Ghobrial, C.E. Freise, and J.F. Trotter A2ALL Study Group. Donor morbidity after living donation for liver transplantation Gastroenterology 135 2008 468 476
246. R.S. Browns Jr Live donors in liver transplantation Gastroenterology 134 2008 1802 1813
247. D.C. Cronin 2nd, and J.M. Millis Living donor liver transplantation: the ethics and the practice Hepatology 47 2008 11 13 (Pubitemid 351171035)
248. F.P. Sarasin, P.E. Majno, and J.M. Llovet Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective Hepatology 33 2001 1073 1079 (Pubitemid 32378205)
249. C.M. Lo, S.T. Fan, and C.L. Liu Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma Br J Surg 94 2007 78 86 (Pubitemid 46142736)
250. R.A. Fisher, L.M. Kulik, and C.E. Freise A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation Am J Transplant 7 2007 1601 1608 (Pubitemid 46776250)
251. L. Kulik, and M. Abecassis Living donor liver transplantation for hepatocellular carcinoma Gastroenterology 127 2004 S277 S282
252. P. Majno, and V. Mazzaferro Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language Liver Transpl 12 2006 896 898 (Pubitemid 43960362)
253. R. Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
254. T. Livraghi, L. Bolondi, and S. Lazzaroni Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients Cancer 15 69 1992 925 929
255. M. Kuang, M.D. Lu, and X.Y. Xie Percutaneous ethanol ablation of early-stage hepatocellular carcinoma by using a multi-pronged needle with single treatment session and high-dose ethanol injection Radiology 253 2009 552 561
256. R. Lencioni, C. Bartolozzi, and D. Caramella Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients Cancer 76 1995 1737 1746
257. T. Livraghi, A. Giorgio, and G. Marin Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection Radiology 197 1995 101 108
258. K.N. Khan, H. Yatsuhashi, and K. Yamasaki Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection J Hepatol 32 2000 269 278 (Pubitemid 30093906)
259. T.I. Huo, Y.H. Huang, and J.C. Wu Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study Scand J Gastroenterol 38 2003 770 778
260. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, and Y.C. Chen Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less Gut 54 2005 1151 1156
261. S. Shiina, T. Teratani, and S. Obi A randomized controlled trial of radiofrequency ablation versus ethanol injection for small hepatocellular carcinoma Gastroenterology 129 2005 122 130 (Pubitemid 41002049)
262. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, and Y.C. Chen Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm Gastroenterology 127 2004 1714 1723
263. R. Lencioni, H.P. Allgaier, and D. Cioni Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection Radiology 228 2003 235 240 (Pubitemid 36736097)
264. F. Brunello, A. Veltri, and P. Carucci Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial Scand J Gastroenterol 43 2008 727 735 (Pubitemid 351868714)
265. Y.K. Cho, J.K. Kim, M.Y. Kim, H. Rhim, and J.K. Han Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies Hepatology 49 2009 453 459
266. G. Germani, M. Pleguezuelo, and K. Gurusamy Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis J Hepatol 52 2010 380 388
267. C. Bouza, T. López-Cuadrado, R. Alcázar, Z. Saz-Parkinson, and J.M. Amate Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma BMC Gastroenterol 9 2009 31
268. J. Imamura, R. Tateishi, and S. Shiina Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma Am J Gastroenterol 103 2008 3057 3062
269. R. Lencioni, D. Cioni, and L. Crocetti C. Early-stage hepatocellular carcinoma in cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation Radiology 234 2005 961 996
270. M. Omata, R. Tateishi, H. Yoshida, and S. Shiina Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation Gastroenterology 127 2004 S159 S166
271. R. Lencioni, and J.M. Llovet Percutanoeus ethanol injection in hepatocellular carcinoma: alive or dead J Hepatol 43 2005 377 380 (Pubitemid 41111416)
272. M.S. Chen, J.Q. Li, and Y. Zheng A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma Ann Surg 243 2006 321 328 (Pubitemid 43327762)
273. J. Huang, L. Yan, and Z. Cheng A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann Surg 252 2010 903 912
274. D.S. Lu, N.C. Yu, and S.S. Raman Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver Radiology 234 2005 954 960 (Pubitemid 40250843)
275. Y. Komorizono, M. Oketani, and K. Sako Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation Cancer 97 2003 1253 1262 (Pubitemid 36237312)
276. J.M. Llovet, R. Vilana, and C. Brú Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma Hepatology 33 2001 1124 1129 (Pubitemid 32378211)
277. T. Teratani, H. Yoshida, and S. Shiina Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations Hepatology 43 2006 1101 1108 (Pubitemid 43724634)
278. N.C. Yu, D.S. Lu, and S.S. Raman Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters - pilot comparison with pathologic findings Radiology 239 2006 269 275
279. T. Shibata, Y. Iimuro, and Y. Yamamoto Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy Radiology 223 2002 331 337 (Pubitemid 34454307)
280. C.M. Pacella, G. Francica, and F.M. Di Lascio Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis J Clin Oncol 27 2009 2615 2621
281. A. Orlacchio, G. Bazzocchi, and D. Pastorelli Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience Cardiovasc Intervent Radiol 31 2008 587 594
282. Y. Guo, Y. Zhang, and R. Klein Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma Cancer Res 70 2010 1555 1563
283. K.K. Ng, R.T. Poon, and S.C. Chan High-intensity focused ultrasound for hepatocellular carcinoma: a single-center experience Ann Surg 253 2011 981 987
284. Wang S, Keltner L, Winship J, Lee W. A Phase 1/2 safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma. J Clin Oncol 2009;27A.
285. J. Bruix, M. Sala, and J.M. Llovet Chemoembolization for hepatocellular carcinoma Gastroenterology 127 2004 S179 188
286. D.B. Brown, J.E. Gould, and D.A. Gervais Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation. Image-guided tumor ablation: standardization of terminology and reporting criteria J Vasc Interv Radiol 20 2009 S377 390
287. D.Y. Lin, Y.F. Liaw, T.Y. Lee, and C.M. Lai Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial Gastroenterology 94 1988 453 456
288. G. Pelletier, A. Roche, and O. Ink A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma J Hepatol 11 1990 181 184
289. Group d'Etude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
290. J. Bruix, J.M. Llovet, and A. Castells Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution Hepatology 27 1998 1578 1583 (Pubitemid 28264682)
291. G. Pelletier, M. Ducreux, and F. Gay Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial J Hepatol 29 1998 129 134 (Pubitemid 28307992)
292. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171 (Pubitemid 34454013)
293. J.M. Llovet, M.I. Real, and X. Montana Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739 (Pubitemid 34607087)
294. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD00477. doi: 10.1002/14651858.CD004787.pub2.
295. J. Lammer, K. Malagari, and T. Vogl Prospective randomised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
296. J.L. Raoul, D. Guyader, and J.F. Bretagne Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma Hepatology 26 1997 1156 1161 (Pubitemid 27509297)
297. R. Salem, R.J. Lewandowski, and M.F. Mulcahy Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
298. L.M. Kulik, B.I. Carr, and M.F. Mulcahy Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis Hepatology 47 2008 71 81 (Pubitemid 351171043)
299. P. Hilgard, M. Hamami, and A.E. Fouly Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
300. B. Sangro, J.I. Bilbao, and M. Iñarrairaegui Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres Dig Dis 27 2009 164 169
301. J.C. Cheng, J.K. Wu, and C.M. Huang Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description Radiother Oncol 63 2002 41 45 (Pubitemid 34626753)
302. Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005;1(23):8739-47. (Pubitemid 46211519)
303. R. Sridhara, J.R. Johnson, and R. Justice Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007 J Natl Cancer Inst 102 2010 230 243
304. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 2006 674 687 (Pubitemid 44286000)
305. A. Villanueva, P. Newell, D.Y. Chiang, S.L. Friedman, and J.M. Llovet Genomics and signaling pathways in hepatocellular carcinoma Semin Liv Dis 27 2007 55 76
306. L.R. Roberts, and G.J. Gores Hepatocellular carcinoma: molecular pathways and new therapeutic targets Semin Liver Dis 25 2005 212 225 (Pubitemid 40781073)
307. D. Semela, and J.F. Dufour Angiogenesis and hepatocellular carcinoma J Hepatol 41 2004 864 880 (Pubitemid 39434320)
308. Y. Ito, T. Takeda, and M. Sakon Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma Br J Cancer 84 2001 1377 1383 (Pubitemid 32522107)
309. D.F. Calvisi, S. Ladu, and A. Gorden Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 2006 1117 1128
310. D.R. Robinson, Y.M. Wu, and S.F. Lin The protein tyrosine kinase family of the human genome Oncogene 19 2000 5548 5557
311. S.M. Wilhelm, L. Adnane, and P. Newell Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 2008 3129 3140
312. A. Villanueva, D.Y. Chiang, and P. Newell Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
313. F. Sahin, R. Kannangai, and O. Adegbola MTOR and P70 S6 kinase expression in primary liver neoplasms Clin Cancer Res 10 2004 8421 8425 (Pubitemid 40053405)
314. T. Takami, P. Kaposi-Novak, and K. Uchida Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis Cancer Res 67 2007 9844 9851 (Pubitemid 47621232)
315. K. Breuhahn, T. Longerich, and P. Schirmacher Dysregulation of growth factor signaling in human hepatocellular carcinoma Oncogene 25 2006 3787 3800 (Pubitemid 43980474)
316. V. Tovar, C. Alsinet, and A. Villanueva IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage J Hepatol 52 2010 550 559
317. A. De La Coste, B. Romagnolo, and P. Billuart Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas Proc Natl Acad Sci USA 95 1998 8847 8851 (Pubitemid 28350577)
318. Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007;1(26):774-780. (Pubitemid 46204256)
319. S. Colnot, T. Decaens, and M. Niwa-Kawakita Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas Proc Natl Acad Sci USA 101 2004 17216 17221 (Pubitemid 39627800)
320. S. Toffanin, Y. Hoshida, and A. Lachenmayer MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a Gastroenterology 140 2011 1618 1628
321. A. Villanueva, and J.M. Llovet Targeted therapies for hepatocellular carcinoma Gastroenterology 140 2011 1410 1426
322. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300. (Pubitemid 46630787)
323. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
324. J.E. Kim, B.Y. Ryoo, and M.H. Ryu Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function Cancer Chemother Pharmacol 68 2011 1285 1290
325. A. Hollebecque, S. Cattan, and O. Romano Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score Aliment Pharmacol Ther 34 2011 1193 1201
326. J.F. Dufour, H. Hoppe, and M.H. Heim Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study Oncologist 15 2010 1198 1220
327. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154-2160.
328. T. Decaens, A. Luciani, and E. Itti J Hepatol 48 2008 S13
329. P.A. Philip, M.R. Mahoney, and C. Allmer Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663 (Pubitemid 46190260)
330. Bekaii-Saab T, Markowitz J, Prescott N, et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15:5895-901.
331. S. Faivre, E. Raymond, and E. Boucher Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
332. A.X. Zhu, D.V. Sahani, and D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
333. D. Koeberle, M. Montemurro, and P. Samaras Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06) Oncologist 15 2010 285 292
334. Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29(suppl):[abstract 4000]
335. J.W. Park, R.S. Finn, and J.S. Kim Phase II, Open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 17 2011 1973 1983
336. A.B. Siegel, E.I. Cohen, and A. Ocean Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
337. M.B. Thomas, J.S. Morris, and R. Chadha Phase II trial of the Combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma J Clin Oncol 27 2009 843 850
338. A.X. Zhu, L.S. Blaszkowsky, and D.P. Ryan Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 1898 1903 (Pubitemid 46638989)
339. J.L. Spratlin, R.B. Cohen, and M. Eadens Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 2010 780 787
340. J. Taieb, J.C. Barbare, and P. Rougier Medical treatments for hepatocellular carcinoma (HCC): what's next? Ann Oncol 10 2006 308 314
341. R.G. Gish, C. Porta, and L. Lazar Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 2007 3069 3075
342. W. Yeo, T.S. Mok, and B. Zee A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 2005 1532 1538 (Pubitemid 41631953)
343. S. Qin, Y. Bai, and S. Ye J Clin Oncol 28 2010 4008A
344. J. Edeline, J.L. Raoul, and E. Vauleon Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study World J Gastroenterol 15 2009 713 716
345. J.C. Barbare, O. Bouché, and F. Bonnetain Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma J Clin Oncol 23 2005 4338 4346 (Pubitemid 46207007)
346. P.K. Chow, B.C. Tai, and C.K. Tan Asian-Pacific Hepatocellular Carcinoma Trials Group. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial Hepatology 36 2002 1221 1226 (Pubitemid 35253439)
347. C. Grimaldi, H. Bleiberg, and F. Gay Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial J Clin Oncol 16 1998 411 417 (Pubitemid 28135581)
348. T.F. Greten, M.P. Manns, and F. Korangy Immunotherapy of hepatocellular carcinoma J Hepatol 45 2006 868 878 (Pubitemid 44646691)
349. T.F. Greten, M.P. Manns, and F. Korangy Immunotherapy of HCC Rev Recent Clin Trials 3 2008 31 39 (Pubitemid 351267024)
350. M. Beaugrand, M. Sala, and F. Degos J Hepatol 42 2003 17A
351. J. Posey, P. Johnson, and T. Mok J Clin Oncol 23 2005 316
352. B.Q. Cheng, C.Q. Jia, and C.T. Liu Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm. A randomized controlled trial JAMA 299 2008 1669 1677
353. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214 (Pubitemid 11167383)
354. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
355. J. Bogaerts, R. Ford, and D. Sargent RECIST Working Party. Individual patient data analysis to assess modifications to the RECIST criteria Eur J Cancer 45 2009 248 260
356. A. Forner, C. Ayuso, and M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
357. R. Gillmore, S. Stuart, and A. Kirkwood EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
358. B. Lambert, E. Sturm, and J. Mertens Intra-arterial treatment with (90)Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital Eur J Nucl Med Mol Imaging 38 2011 2117 2124
359. M. Iavarone, G. Cabibbo, and F. Piscaglia Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy Hepatology 54 2011 2055 2063
360. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2011. doi:10.1002/cncr.26255.